Tracy Graham
YOU?
Author Swipe
View article: Treatment of infertility and risk of breast cancer among women with a BRCA pathogenic variant: a matched case-control study
Treatment of infertility and risk of breast cancer among women with a BRCA pathogenic variant: a matched case-control study Open
Background The global trend toward delayed childbearing has led to an increased use of fertility treatment, including in vitro fertilization (IVF) and hormonal medications. Concerns regarding the potential impact of these interventions on …
View article: Opportunistic screening for broad range of medically relevant secondary findings: Laboratory benefits and burdens
Opportunistic screening for broad range of medically relevant secondary findings: Laboratory benefits and burdens Open
While the yield of reportable SFs was high, this was accompanied by many non-reportable VUS and increased efforts for exome analysis.
View article: “Should I Let Them Know I Have This?”: Multifaceted Genetic Discrimination and Limited Awareness of Legal Protections among Individuals with Hereditary Cancer Syndromes
“Should I Let Them Know I Have This?”: Multifaceted Genetic Discrimination and Limited Awareness of Legal Protections among Individuals with Hereditary Cancer Syndromes Open
Introduction: Hereditary cancer syndromes (HCS), such as hereditary breast and ovarian cancer syndrome (HBOC) and Lynch syndrome (LS), represent approximately 10% of all cancers. Along with medical burdens associated with the genetic risk …
View article: Genetics Adviser: The development and usability testing of a new patient digital health application to support clinical genomic testing
Genetics Adviser: The development and usability testing of a new patient digital health application to support clinical genomic testing Open
The Genetics Adviser is a comprehensive, interactive, patient-centered application found to have high acceptability and usability for pre- and post-test genomic testing, counseling, and return of results adaptable for multiple testing plat…
View article: P523: Returning all clinically relevant findings from genomic sequencing: Preliminary results from the incidental genomics RCT
P523: Returning all clinically relevant findings from genomic sequencing: Preliminary results from the incidental genomics RCT Open
While guidelines prioritize the return of medically actionable secondary findings (SFs) from genomic sequencing (GS), practice is shifting toward returning a broader range of results to patients and research participants, including variant…
View article: P867: “I worry I don’t have control”: The psychosocial impacts of living with a hereditary cancer syndrome
P867: “I worry I don’t have control”: The psychosocial impacts of living with a hereditary cancer syndrome Open
Hereditary cancer syndromes (HCS) are one of the most common forms of inherited diseases, accounting for up to 10% of cancers. Hereditary Breast and Ovarian Cancer Syndrome (HBOC) and Lynch Syndrome (LS) are the most prevalent types of HCS…
View article: P538: Curious but cautious: Patients’ preferences for all types of clinically actionable genomic incidental results
P538: Curious but cautious: Patients’ preferences for all types of clinically actionable genomic incidental results Open
Genomic sequencing (GS) can generate a large volume of incidental results (IR), findings that are unrelated to the primary indication, but which can have varying levels of medical actionability. Guidelines (eg, ACMG) recommend that patient…
View article: P555: Clinical utility returning of all types of medically relevant genomic sequencing findings: An observational study
P555: Clinical utility returning of all types of medically relevant genomic sequencing findings: An observational study Open
Guidelines prioritize medically actionable secondary findings (SFs), but a broader spectrum of clinically relevant results could be analyzed and returned. However, evidence on the clinical outcomes of returning results beyond medically act…
View article: P881: Revealing the hidden costs: Exploring the financial toxicity of hereditary cancer syndromes
P881: Revealing the hidden costs: Exploring the financial toxicity of hereditary cancer syndromes Open
Financial toxicity, also known as financial distress or burden, refers to the harmful effects caused by the high costs of treatment on patients' well-being. Although financial toxicity is widely reported in cancer patients, there is limite…
View article: P892: “Should I let them know I have this?”: Concerns and experiences of genetic discrimination amongst individuals with hereditary cancer syndromes
P892: “Should I let them know I have this?”: Concerns and experiences of genetic discrimination amongst individuals with hereditary cancer syndromes Open
Hereditary cancer syndromes (HCS) account for approximately 10% of all cancers. Among HCS, Hereditary Breast and Ovarian Cancer Syndrome (HBOC) and Lynch Syndrome (LS) are the most prevalent. In addition to medical burdens associated with …
View article: P553: How do patients with hereditary cancer syndromes navigate the healthcare system? A qualitative comparative study across Canada
P553: How do patients with hereditary cancer syndromes navigate the healthcare system? A qualitative comparative study across Canada Open
Hereditary cancer syndromes (HCS) account for 5-10% of all cancers. HCSs such as hereditary breast and ovarian cancer syndrome (HBOC) or Lynch syndrome (LS) can increase one's lifetime risk of cancer by over 80%. HCS patients therefore req…
View article: Genetic testing women with newly diagnosed breast cancer: What criteria are the most predictive of a positive test?
Genetic testing women with newly diagnosed breast cancer: What criteria are the most predictive of a positive test? Open
Background Knowledge of pathogenic variants in cancer‐predisposing genes is important when making breast cancer treatment decisions, but genetic testing is not universal and criteria must be met to qualify for genetic testing. The objectiv…
View article: A comprehensive genomic reporting structure for communicating all clinically significant primary and secondary findings
A comprehensive genomic reporting structure for communicating all clinically significant primary and secondary findings Open
Genomic sequencing (GS) can reveal secondary findings (SFs), findings unrelated to the reason for testing, that can be overwhelming to both patients and providers. An effective approach for communicating all clinically significant primary …
View article: Genetics Adviser: a protocol for a mixed-methods randomised controlled trial evaluating a digital platform for genetics service delivery
Genetics Adviser: a protocol for a mixed-methods randomised controlled trial evaluating a digital platform for genetics service delivery Open
Introduction The high demand for genetic tests and limited supply of genetics professionals has created a need for alternative service delivery models. Digital tools are increasingly being used to support multiple points in the genetic tes…
View article: Health outcomes, utility and costs of returning incidental results from genomic sequencing in a Canadian cancer population: protocol for a mixed-methods randomised controlled trial
Health outcomes, utility and costs of returning incidental results from genomic sequencing in a Canadian cancer population: protocol for a mixed-methods randomised controlled trial Open
Introduction Genomic sequencing has rapidly transitioned into clinical practice, improving diagnosis and treatment options for patients with hereditary disorders. However, large-scale implementation of genomic sequencing faces challenges, …
View article: PO-334 Distribution of copy number alterations defines clonal populations involved in the evolutionary transition from adenoma-to-carcinoma in colorectal cancer
PO-334 Distribution of copy number alterations defines clonal populations involved in the evolutionary transition from adenoma-to-carcinoma in colorectal cancer Open
Introduction Colorectal cancer progresses in a multi-step manner with adenoma being the most well-known precursor lesion. Malignant polyps, which are adenomas containing a focus of adenocarcinoma, are suitable models to study the evolutio…
View article: Evaluation of a decision aid for incidental genomic results, the Genomics ADvISER: protocol for a mixed methods randomised controlled trial
Evaluation of a decision aid for incidental genomic results, the Genomics ADvISER: protocol for a mixed methods randomised controlled trial Open
Introduction Genome sequencing, a novel genetic diagnostic technology that analyses the billions of base pairs of DNA, promises to optimise healthcare through personalised diagnosis and treatment. However, implementation of genome sequenci…